A potent formula against Triple-negative Breast Cancer - Sorafenib-Carbon Nanotubes- Folic Acid: Targeting, Apoptosis triggering, and bioavailability enhancing

Author:

Nabawi Hossam M. S.1,Abdelazem Ahmed Z.1,Rouby Waleed M.A. El1,El-Shahawy Ahmed A. G.1

Affiliation:

1. Beni-Suef University

Abstract

Abstract Triple-negative breast cancer (TNBC) has short survival rates, a high recurrence rate, aggressive clinical behavior, a high risk of metastasis and it is difficult to be targeted by ordinary medicines. This study aimed to (i) prepare a novel formula of sorafenib, carbon nanotubes, and folic acid to be tested as a drug delivery system targeting TNBC with higher safety and efficacy compared with free sorafenib and to (ii) evaluate the formula stability, in vitro pharmacodynamic, and in vivo pharmacokinetic properties. The formula preparation was done by the synthesis of polyethylene glycol bis amine linker, carbon nanotube pegylation, folic acid attachment, and sorafenib loading. The prepared formula has been characterized using XRD, FTIR, 1HNMR, UV, HR-TEM, FESEM, Zeta sizer and Zeta potential. In vitro studies included drug release determination, MTT assay, flow cytometry to determine the apoptotic stage with percent, cell cycle analysis, and apoptotic marker assays for caspase-3, 8, 9, cytochrome c, and BCL-2. The in vivo study was performed to determine bioavailability and half-life in rats. The in vitro MTT anti-proliferative assay revealed that the formula was 3-fold more cytotoxic towards TNBC cells than free sorafenib, and the flow cytometry showed a significant increase in apoptosis and necrosis. The formula has a greater inhibitory effect on BCL-2 and a lessening effect on cytochrome c and caspases 3, 8, and 9 than free sorafenib. Moreover, in vivo experiments proved that our novel formula was superior to free sorafenib by increasing bioavailability by eight times and prolonging the half-life by three times. These results confirmed the successful preparation of the desired formula with better pharmacodynamic and pharmacokinetic properties. These promising results may show a novel therapeutic strategy for TNBC patients.

Publisher

Research Square Platform LLC

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3